Creative Medical Technology Holdings, Inc. (CELZ) Balance Sheet

The consistent contraction in the asset base suggests that the company is effectively liquidating its balance sheet to fund ongoing operating losses. Investors should monitor this trajectory, as the lack of asset replacement indicates that the business model is not currently generating the internal returns necessary to sustain its own scale.

While the current ratio remains high due to the lack of significant short-term liabilities, this metric is misleading as it masks the underlying cash burn rate. The company's liquidity is essentially a finite resource that is being depleted to support R&D, necessitating a successful clinical or commercial catalyst before the runway is exhausted.

The negative retained earnings position indicates that the company has yet to achieve a profitable operating cycle, effectively consuming the capital provided by shareholders. This trend warrants further investigation into whether future equity raises will be required to offset the ongoing depletion of the company's book value.